Corneal Ulcers - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Corneal Ulcers - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Corneal Ulcers - Pipeline Review, H2 2015', provides an overview of the Corneal Ulcers's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Corneal Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Ulcers and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Corneal Ulcers
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Corneal Ulcers and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Corneal Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Corneal Ulcers pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Corneal Ulcers
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Corneal Ulcers pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Corneal Ulcers Overview 6
Therapeutics Development 7
Pipeline Products for Corneal Ulcers - Overview 7
Pipeline Products for Corneal Ulcers - Comparative Analysis 8
Corneal Ulcers - Therapeutics under Development by Companies 9
Corneal Ulcers - Therapeutics under Investigation by Universities/Institutes 10
Corneal Ulcers - Pipeline Products Glance 11
Early Stage Products 11
Corneal Ulcers - Products under Development by Companies 12
Corneal Ulcers - Products under Investigation by Universities/Institutes 13
Corneal Ulcers - Companies Involved in Therapeutics Development 14
Amakem NV 14
Digna Biotech, S.L. 15
Lee's Pharmaceutical Holdings Limited 16
Corneal Ulcers - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
AMA-0526 - Drug Profile 26
Mechanism of Action 26
R&D Progress 26
disitertide - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
LQ-7 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
P-17 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules for Parasitic Corneal Ulcers - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ZK-003 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Corneal Ulcers - Recent Pipeline Updates 35
Corneal Ulcers - Dormant Projects 36
Corneal Ulcers - Discontinued Products 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables

Number of Products under Development for Corneal Ulcers, H2 2015 7
Number of Products under Development for Corneal Ulcers - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 11
Products under Development by Companies, H2 2015 12
Products under Investigation by Universities/Institutes, H2 2015 13
Corneal Ulcers - Pipeline by Amakem NV, H2 2015 14
Corneal Ulcers - Pipeline by Digna Biotech, S.L., H2 2015 15
Corneal Ulcers - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 16
Assessment by Monotherapy Products, H2 2015 17
Number of Products by Stage and Target, H2 2015 19
Number of Products by Stage and Mechanism of Action, H2 2015 21
Number of Products by Stage and Route of Administration, H2 2015 23
Number of Products by Stage and Molecule Type, H2 2015 25
Corneal Ulcers Therapeutics - Recent Pipeline Updates, H2 2015 35
Corneal Ulcers - Dormant Projects, H2 2015 36
Corneal Ulcers - Discontinued Products, H2 2015 37